On 11 September 2024, the latest results from the FLOW trial were presented at the European Association for the Study of Diabetes (EASD) conference in Madrid, Spain. The FLOW trial, initiated in 2019, was a global, multinational, randomized controlled trial conducted across 28 countries, 387 sites, and 3,533 participants. Adults with type 2 diabetes (T2D) and chronic kidney disease (CKD) were randomized in a 1:1 ratio to receive either once-weekly semaglutide 1.0 mg alongside standard care or a placebo with standard care.
CKD is common among adults with T2D, and both GLP-1 receptor agonists (GLP-1RAs) and SGLT-2i have shown benefits in reducing cardiovascular and k...